Stock CLS B CLINICAL LASERTHERMIA SYSTEMS AB
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Clinical Laserthermia Systems AB

Equities

CLS B

SE0022049920

Market Closed - Nasdaq Stockholm
Other stock markets
 11:23:02 2024-05-14 am EDT 		5-day change 1st Jan Change
14.3 SEK -3.08% Intraday chart for Clinical Laserthermia Systems AB -2.92% -48.18%
Apr. 30 Clinical Laserthermia Notes US FDA Clearance for ClearPoint's Prism Bone Anchor Accessory MT
Apr. 11 Clinical Laserthermia Systems AB Presents Initial Data from the Investigator Initiated Trial at Radboud University Medical Center Using the CLS Transberg System CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
CLS launches its Focal Laser Ablation system for prostate cancer in France in collaboration with MTEC Company
AQ
CLS partner ClearPoint Neuro receives FDA 510(k) clearance for Prism Bone Anchor Accessory enabling operating room placement of laser applicators
AQ
Clinical Laserthermia Systems announces timetable and additional information for the upcoming reverse share split
AQ
Bulletin from the Extraordinary General Meeting on Friday 12th of April in Clinical Laserthermia Systems AB
AQ
BioStock: CLS makes progress in prostate cancer in Europe and the US
AQ
Initial data presented from the Investigator Initiated Trial (IIT) at Radboud University Medical Center using the CLS TRANBERG[®] system
AQ
CLS receives second order from the National Institutes of Health Clinical Center in the US
AQ
As part of CLS expansion in Europe prostate cancer patients have been treated with CLS TRANBERG Thermal Therapy System for the first time in Italy
AQ
CLS signs agreement with ROSE Urology for treatment of prostate cancer patients with TRANBERG Thermal Therapy System
AQ
CLS appoints Håkan Rosqvist as interim CFO
AQ
Notice of Extraordinary General Meeting at Clinical Laserthermia Systems AB
AQ
Publication in Journal of Neurosurgery Demonstrates Distinct Advantages of CLS's Core Technology in Neurosurgical MR-guided Laser Ablation
AQ
BioStock: CLS sees opportunity to increase revenue
AQ
Clinical Laserthermia Systems AB publishes Year-end report January - December 2023
AQ
Clinical Laserthermia Systems announces that the date for conversion of interim shares is estimated to February 21, 2024
AQ
Clinical Laserthermia Systems will receive ca SEK 23.5 million in connection with the warrant exercise and underwriting commitments for TO 6 B, corresponding to a subscription rate of 100 percent.
AQ
Last day of trading in warrants of series TO 6 B is today February 2, 2024
AQ
Clinical Laserthermia Systems AB enters into top down underwriting commitments in the ongoing exercise of warrants of series TO 6 B totaling SEK 7 million.
AQ
CLS has filed a new patent application for expanded and extended protection of the company's technology for laser-based tissue ablation until 2044.
AQ
Senior executives and larger owner exercise, pro rata, warrants of series TO 6 B for approximately SEK 0.7 million.
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CLS B Stock
  4. News Clinical Laserthermia Systems AB
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW